Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22971327 | 0.78 | NPC1 (0.50) | NPC1RAB9AIGF1RMAPK10PLK4 | |
| SCHEMBL30206206 | 0.78 | PLK4 (0.59) | NPC1RAB9AIGF1RMAPK10PLK4 | |
| SCHEMBL22970759 | 0.75 | CDK4 (0.47) | NPC1RAB9ACHEK1KARS1CHEK2 | |
| SCHEMBL22970904 | 0.75 | CDK4 (0.49) | NPC1RAB9ACHEK1KARS1CHEK2 | |
| SCHEMBL22970768 | 0.75 | CHEK1 (0.65) | NPC1RAB9ACHEK1CHEK2TP53 | |
| SCHEMBL22971435 | 0.72 | KDM4E (0.41) | NPC1RAB9ACHEK1KARS1CHEK2 | |
| SCHEMBL10086655 | 0.71 | KDM4E (0.55) | MAPK10PLK4MAPTPIK3CA | |
| SCHEMBL22971279 | 0.71 | KARS1 (0.52) | NPC1RAB9ACHEK1KARS1CHEK2 | |
| SCHEMBL22970965 | 0.71 | KARS1 (0.49) | CHEK1KARS1CHEK2HRH4 | |
| SCHEMBL30008119 | 0.70 | JAK2 (0.66) | CHEK1MAPK10PLK4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | NPC1 2871/4885RAB9A 3697/4885CHEK1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.